These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review. Obara K, Masuzawa M, Amoh Y. J Dermatol; 2018 May 25; 45(5):587-591. PubMed ID: 29352490 [Abstract] [Full Text] [Related]
49. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD. JAMA Oncol; 2015 Jul 25; 1(4):433-40. PubMed ID: 26181250 [Abstract] [Full Text] [Related]
50. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM, Freeman GJ, McDermott DF. Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918 [Abstract] [Full Text] [Related]
51. Nivolumab: A Review in Advanced Melanoma. Scott LJ. Drugs; 2015 Aug 01; 75(12):1413-24. PubMed ID: 26220912 [Abstract] [Full Text] [Related]
53. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. Kanno H, Ishida K, Yamada W, Nishida T, Takahashi N, Mochizuki K, Mizuno Y, Matsuyama K, Takahashi T, Seishima M. J Infect Chemother; 2017 Nov 01; 23(11):774-777. PubMed ID: 28527652 [Abstract] [Full Text] [Related]
54. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus. Qiu J, Luo S, Yin W, Li X, Zhou Z. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan 28; 48(1):49-58. PubMed ID: 36935177 [Abstract] [Full Text] [Related]
55. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability? Marchand L, Reffet S, Dalle S, Disse E, Vouillarmet J, Cugnet-Anceau C, Thivolet C. Acta Diabetol; 2019 Mar 28; 56(3):377-378. PubMed ID: 30506459 [No Abstract] [Full Text] [Related]